Wells Fargo lowered the firm’s price target on NeuroPace (NPCE) to $13 from $15 and keeps an Overweight rating on the shares. The firm notes the company reported Q3 revenues well ahead of Wells’ and consensus estimates. Management increased revenue guidance for the year again, but held the line on OpEx andGM guidance, the firm adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NPCE: